PMID- 19030182
OWN - NLM
STAT- MEDLINE
DCOM- 20090924
LR  - 20191210
IS  - 1520-6777 (Electronic)
IS  - 0733-2467 (Linking)
VI  - 28
IP  - 5
DP  - 2009
TI  - Psychometric validation of the overactive bladder satisfaction with treatment 
      questionnaire (OAB-SAT-q).
PG  - 416-22
LID - 10.1002/nau.20672 [doi]
AB  - AIMS: Valid and reliable questionnaires must be used to accurately assess 
      patients' satisfaction with overactive bladder (OAB) treatment. This study 
      evaluated the reliability and validity of the OAB Satisfaction with Treatment 
      Questionnaire (OAB-SAT-q). METHODS: This was a secondary analysis of clinical 
      study data of patients randomized to darifenacin or darifenacin plus Behavioral 
      Modification Program. Patients completed the Overactive Bladder Questionnaire 
      (OAB-q) and a 3-day bladder diary at Baseline and Week 12 and the OAB-SAT-q at 
      Week 12. Internal consistency reliability was assessed by Cronbach's alpha. 
      Concurrent validity was assessed through correlations with OAB-q change scores 
      and adverse events (AEs). Discriminant validity was assessed among subgroups 
      using general linear models. RESULTS: Analyses utilized a per-protocol population 
      (completion of OAB-q at Baseline and OAB-q and OAB-SAT-q at Week 12) (n = 375). 
      Exploratory factor analysis of the OAB-SAT-q revealed three 3-item subscales 
      (Satisfaction, Side Effects, Endorsement) and two single items (Convenience, 
      Preference). Cronbach's alphas = 0.84-0.95. Subscale-to-subscale correlations = 
      0.10-0.67 (all P < 0.01 except Side Effects and Convenience). The Side Effects 
      subscale significantly correlated with number of treatment-related AEs (r = 0.27; 
      P < 0.01) and discriminated between patients with/without dry mouth and patients 
      with/without constipation. The Satisfaction and Endorsement subscales 
      discriminated between patients who worsened or had no change in micturition 
      frequency and urinary urgency and patients who had a reduction of >3 episodes 
      (all P < 0.001). The OAB-SAT-q does not appear to discriminate by incontinence 
      episodes. CONCLUSION: The OAB-SAT-q demonstrated good psychometric properties in 
      this initial evaluation-including internal consistency reliability and concurrent 
      and discriminant validity-and appears to be a useful assessment of OAB treatment 
      satisfaction. Neurourol. Urodynam. 28:416-422, 2009. (c) 2008 Wiley-Liss, Inc.
FAU - Margolis, Mary Kay
AU  - Margolis MK
AD  - United BioSource Corporation, Center for Health Outcomes Research, Bethesda, 
      Maryland, USA. marykay.margolis@unitedbiosource.com
FAU - Fox, Kathleen M
AU  - Fox KM
FAU - Cerulli, Annamaria
AU  - Cerulli A
FAU - Ariely, Rinat
AU  - Ariely R
FAU - Kahler, Kristijan H
AU  - Kahler KH
FAU - Coyne, Karin S
AU  - Coyne KS
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Neurourol Urodyn
JT  - Neurourology and urodynamics
JID - 8303326
RN  - 0 (Benzofurans)
RN  - 0 (Muscarinic Antagonists)
RN  - 0 (Pyrrolidines)
RN  - APG9819VLM (darifenacin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - *Behavior Therapy
MH  - Benzofurans/adverse effects/*therapeutic use
MH  - Combined Modality Therapy
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Muscarinic Antagonists/adverse effects/*therapeutic use
MH  - *Patient Satisfaction
MH  - *Psychometrics
MH  - Pyrrolidines/adverse effects/*therapeutic use
MH  - Randomized Controlled Trials as Topic
MH  - Reproducibility of Results
MH  - *Surveys and Questionnaires
MH  - Time Factors
MH  - Treatment Outcome
MH  - Urinary Bladder, Overactive/physiopathology/psychology/*therapy
MH  - Urodynamics
EDAT- 2008/11/26 09:00
MHDA- 2009/09/25 06:00
CRDT- 2008/11/26 09:00
PHST- 2008/11/26 09:00 [pubmed]
PHST- 2009/09/25 06:00 [medline]
PHST- 2008/11/26 09:00 [entrez]
AID - 10.1002/nau.20672 [doi]
PST - ppublish
SO  - Neurourol Urodyn. 2009;28(5):416-22. doi: 10.1002/nau.20672.